Cell-potent and Selective Inhibitors of Nicotinamide N-methyltransferase for Disease Treatment

Back to all technologies
Download as PDF
NCS: Researchers at Purdue University have synthesized a series of cell-potent and selective inhibitors of nicotinamide N-methyltransferase (NNMT) that can be used to treat cancer, metabolic and neurodegenerative diseases. NNMT plays an important role in regulating both epigenetics and metabolism by methylating nicotinamide. Elevated levels of NNMT have been associated with diseases like cancer, liver disease, diabetes, and obesity. The most potent compound (IC50 =3.4 nM) synthesized by the Purdue researchers had an IC50 value of 100 nanomolar for inhibiting N-methylated Nicotinamide in cells, over 1000-fold selectivity for NNMT compared to related methyltransferases. Moreover, cell-potent NNMT inhibitors exhibit a favorable pharmacokinetics profile.

Related Publications: Chen D, Li L, Diaz K, Iyamu ID, Yadav R, Noinaj N, Huang R. (2019) Novel propargyl-linked bisubstrate analogs as tight-binding Inhibitors for nicotinamide N-methyltransferase. Journal of Medicinal Chemistry. 62 (23), 10783-10797. PMID: 31724854; PMCID: PMC7296983. www.ncbi.nlm.nih.gov/pubmed/31724854

Iyamu ID, Vilseck JZ, Yadav R, Noinaj N, Huang R. (2022) Exploring unconventional SAM analogues to build cell-potent bisubstrate inhibitors for nicotinamide N-methyltransferase. Angewandte Chemie International Edition.  https://doi.org/10.1002/anie.202114813


- Selective

- Low concentration


-Metabolic disorders


-Neurodegenerative diseases
Nov 21, 2022

Nov 22, 2021
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org